Acyl‐ghrelin has demonstrated promising therapeutic potential for central nervous system (CNS) diseases, including AD, PD, Huntington's disease, and ALS.[7, 32, 33, 34] For example, ghrelin has been shown to disrupt amyloid beta (Aβ) plaques, inhibit tau protein hyperphosphorylation, and mitigate mitochondrial dysfunction, offering potential benefits for AD treatment.[32] Body weight loss, systemic and cellular metabolism impairments, and insulin‐like growth factor‐1 (IGF‐1) reductions are highly associated with faster disease progression and worsening disease outcomes in ALS patients. This evidence concerns the gene GHRL and amyotrophic lateral sclerosis.